RE: FpML-EQD FpML EQD WG 14:00 LDN TUESDAY 15 Dec 2009

PLEASE NOTE : This meeting is tomorrow, to fit the diaries on many active contributors

* Telephone Conference

US: 1 888 481 3032

UK: 0 800 904 7961

Intl: 1 617 801 9600

Participant code: 8682747

* Agenda

=== 1. Action items from our last meeting 14:00 LDN Fri 04 Dec 2009 ===

AP contribute improved documentation for <currency> element of underlyers such as Equity

IY propose clarification of currency for various purposes on underlyer ( listing, trading )

IY propose further addition and correction of MCA and MCA Annex coding scheme values

IY add AEJ 2009 Closed Market Changes proposal from JC for FpML-4-7

IY add MEA II proposal from TA for FpML-4-7

=== 2. Proposed new representatives ===

Please review CV / Bio. information circulated to the email list

2.1 Niraj Kumar, Wipro Technologies

2.2 Imthiyaz Sikkander, Barclays Capital

2.3 Mary Kwok, MarkitSERV

New members should feel free to put questions to the group

=== 3. ISDA Legal Drafting ===

Ongoing ISDA "Legacy" Legal Drafting has several structural consequences for FpML

== 3.1 Multiple Exchange Annex ( MEA ) II Proposal : FpML-4-7, Q4 2009 ==

Open question ( IY/TA )

"The annex name is ‘Multiple Exchange Index Annex’ so the scheme values should have the word ‘Index’. As for the element and scheme names, it may not be essential to include ‘Index’ if we want to keep them short, but I’d seek WG/Andrew’s opinion"

[ AP : We should follow ISDA legal wording, they use "MultipleExchangeAnnex", so we should call the element <multipleExchangeAnnex> ]

== 3.2 EU Index ( Client ) Swap : FpML-4-8, Q1 2010 ==

3.2.1 Compounding Date

Treatment and support ( CY )

"We are finalizing business logic for Q1 deliveries. For Compounding, as of November 19th release, we added the Compounding field (you would populate the Compounding field with "Y" when it's applicable).

For Compounding Date, please confirm if the following logic works for you.

Compounding: Y

Compounding Dates: [date] [date] [date] (you will list all relevant dates)

>>> this field is required when Compounding is populated with Y.

If you are planning to have a default for Compounding Dates in GTC, then we can make this field optional. However, you still need to "list" dates when you are submitting this field.

Please kindly advise your thought on this by COB Tuesday (NY time) next week."

3.2.2 Component Security Index Annex

Not Applicable / Footnote. Could this evolve from a boolean ( Applicable / Not Applicable ) to a range of Annex values as per MEA ?

== 3.3 PAISS : FpML-4-8, Q1 2010 ==

ISDA Counsel have made intensive efforts to solicit feedback and finalise this draft

Calls are scheduled 10:00 HKG on Tue 15 Dec 2009 and Thu 17 Dec to discuss feedback

== 3.4 US ( Client ) Option : FpML-4-8, Q1 2010 ==

Pre publication draft from ISDA Legal Department on Fri 11 Dec 2009

"Attached please find the pre-publication draft (clean and marked versions) of Annex ISO to the 2009 Americas Master Equity Derivatives Confirmation Agreement.

Substantive edits to the draft have been made in respect of:

• Exchange – multiple exchange consequences have been provided for;

• Settlement Currency – specified as USD;

• Futures Price Valuation – language revised to provide for expiry dates that would fall on a Saturday;

• Latest Exercise Time – Election added to the T-Supp; provisions added w/r/t multiple exchanges and the Latest Exercise Time on an Expiration Date

• Share Adjustment Events – additional elections provided for under Cancellation and Payment;

• Stock Loan Rate – field added for Agreed Model.

Please review and provide any comments COB December 14 after which date the document will be published."

=== 4. NY Fed OTC Commitments ===

=== 5. Next Meeting ===

Propose 14:00 LDN Fri 08 Jan 2010

=== 6. Thanks from the Chair ===

Thank you all for your contributions this year, we have collaborated to deliver a very demanding book of work

=== 7. AOB ===

This communication is for informational purposes only. It is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect those of JPMorgan Chase & Co., its subsidiaries and affiliates. This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. Thank you. Please refer to http://www.jpmorgan.com/pages/disclosures for disclosures relating to European legal entities.